Lawmakers Urge FDA to Restrict Chinese Clinical Data After Trial Deaths

Two Republican legislators have called on the FDA to reject clinical trial data from Chinese sites unless those sites have been audited by the agency recently. They also want a comprehensive review of existing products that rely on Chinese-generated data. The request follows reported deaths in investigator-initiated trials in China.